---
title: Improve walking using visual feedback
nct_id: NCT07322939
phase: NA
status: RECRUITING
sponsor: Hasan Kalyoncu University
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07322939"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07322939"
last_fetched: "2026-05-10T14:01:33.997Z"
source: "Parkinson's Pathways (curated)"
---
# Improve walking using visual feedback

**Goal (in five words):** Improve walking using visual feedback

**Official Title:** Effects of Visual Indicator Exercises for the Trunk and Lower Extremities on Activity and Participation in Parkinson's Disease

**Trial ID:** [NCT07322939](https://clinicaltrials.gov/study/NCT07322939)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Hasan Kalyoncu University
- **Target Enrollment:** 32 participants
- **Start Date:** 2025-12-01
- **Completion Date:** 2026-04-05
- **Conditions:** Parkinson Disease, Balance Impairment, Exercise Training, Postural Control
- **Interventions:** Control Group, Visual Feedback Exercise Group
- **Intervention Types:** OTHER

## Summary For Families

Researchers want to know whether using visual indicators during trunk and lower limb exercises can improve balance, posture, mobility, and participation in daily life for people with Parkinson's. The program gives real-time visual cues so you can see and correct trunk alignment and weight shifts, with the aim of retraining balance reactions and making gait and functional movements steadier; it is a non-drug rehabilitation approach used alongside your oral antiparkinsonian meds, not a replacement. Outcomes with the visual feedback program are compared to a control group that does the same exercise program without the visual indicators. Adults 18 to 85 with idiopathic Parkinson's at Hoehn and Yahr stages 1 to 3 who are on oral antiparkinsonian treatment only can join, while people with major musculoskeletal, cardiovascular, vestibular, other neurological or psychiatric disorders, or poor vision are excluded.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 85 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria

* Individuals diagnosed with idiopathic Parkinson's disease
* Disease severity classified as stage 1 to 3 according to the Modified Hoehn and Yahr Scale
* Patients receiving oral antiparkinsonian treatment only

Exclusion Critera

* Presence of musculoskeletal, cardiovascular, or vestibular disorders that may interfere with the completion of the assessments or treatment protocol
* Presence of additional neurological or psychiatric disorders other than Parkinson's disease
* Presence of visual impairment insufficient to perceive visual feedback
```

## Locations (1)

- Hasan Kalyoncu University, Gaziantep, Şahinbey, Turkey (Türkiye) _(37.0594, 37.3825)_
  - Günseli Usgu, Assoc. Prof. — (CONTACT) — +90 ( 342 ) 211 80 81 — info@hku.edu.tr

## Central Contacts

- Büşra Akıncı, MSc — (CONTACT) — +90 (541) 976 55 83 — busra.tufekci@hotmail.com
- Günseli Usgu, Assoc. Prof. — (CONTACT) — gunseli.usgu@hku.edu.tr

---

*Canonical: https://parkinsonspathways.com/trial/NCT07322939*  
*HTML version: https://parkinsonspathways.com/trial/NCT07322939*  
*Source data: https://clinicaltrials.gov/study/NCT07322939*